Cargando…

COMP (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic Carotid Stenosis

OBJECTIVE: COMP (cartilage oligomeric matrix protein) is abundantly expressed in the cardiovascular system, cartilage, and atherosclerotic plaques. We investigated if the total COMP (COMPtotal) and COMP neoepitope (COMPneo) with other cardiovascular markers and clinical parameters could identify sym...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandstedt, Joakim, Vargmar, Karin, Björkman, Kristina, Ruetschi, Ulla, Bergström, Göran, Hultén, Lillemor Mattsson, Skiöldebrand, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901532/
https://www.ncbi.nlm.nih.gov/pubmed/33472398
http://dx.doi.org/10.1161/ATVBAHA.120.314720
_version_ 1783654391879827456
author Sandstedt, Joakim
Vargmar, Karin
Björkman, Kristina
Ruetschi, Ulla
Bergström, Göran
Hultén, Lillemor Mattsson
Skiöldebrand, Eva
author_facet Sandstedt, Joakim
Vargmar, Karin
Björkman, Kristina
Ruetschi, Ulla
Bergström, Göran
Hultén, Lillemor Mattsson
Skiöldebrand, Eva
author_sort Sandstedt, Joakim
collection PubMed
description OBJECTIVE: COMP (cartilage oligomeric matrix protein) is abundantly expressed in the cardiovascular system, cartilage, and atherosclerotic plaques. We investigated if the total COMP (COMPtotal) and COMP neoepitope (COMPneo) with other cardiovascular markers and clinical parameters could identify symptomatic carotid stenosis. APPROACH AND RESULTS: Blood samples were collected from patients with symptomatic carotid stenosis (stenosis, n=50), patients with stroke without carotid stenosis but small plaques (plaque, n=50), and control subjects (n=50). COMPtotal and COMPneo were measured using an ELISA. Ninety-two cardiovascular disease markers were measured by the Olink CVD kit. The presence of native COMP and COMPneo was determined by immunohistochemistry. The concentration of COMPneo was higher and COMPtotal was lower in the stenosis group. When the concentration was compared between the stenosis and control groups, IL-1ra (interleukin-1 receptor antagonist protein), IL6 (interleukin-6), REN (Renin), MMP1 (matrix metalloproteinase-1), TRAIL-R2 (tumor necrosis factor-related apoptosis-inducing ligand receptor 2), ITGB1BP2 (integrin beta 1 binding protein 2), and COMPneo were predictive of stenosis. Conversely, KLK6 (kallikrein-6), COMPtotal, NEMO (nuclear factor-kappa-B essential modulator), SRC (Proto-oncogene tyrosine-protein kinase Src), SIRT2 (SIR2-like protein), CD40 (cluster of differentiation 40), TF (tissue factor), MP (myoglobin), and RAGE (receptor for advanced glycation end-products) were predictive of the control group. Model reproducibility was good with the receiver operating characteristic plot area under the curve being 0.86. When comparing the plaque group and stenosis group, COMPneo, GAL (galanin), and PTX3 (pentraxin-related protein PTX3) were predictive of stenosis. Model reproducibility was excellent (receiver operating characteristic plot area under the curve 0.92). COMPneo was detected in smooth muscle-, endothelial-, and foam-cells in carotid stenosis. CONCLUSIONS: Degradation of COMP may be associated with atherosclerosis progression and generation of a specific COMP fragment—COMPneo. This may represent a novel biomarker that together with COMPtotal and other risk-markers could be used to identify symptomatic carotid stenosis.
format Online
Article
Text
id pubmed-7901532
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-79015322021-02-24 COMP (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic Carotid Stenosis Sandstedt, Joakim Vargmar, Karin Björkman, Kristina Ruetschi, Ulla Bergström, Göran Hultén, Lillemor Mattsson Skiöldebrand, Eva Arterioscler Thromb Vasc Biol Clinical and Population Studies OBJECTIVE: COMP (cartilage oligomeric matrix protein) is abundantly expressed in the cardiovascular system, cartilage, and atherosclerotic plaques. We investigated if the total COMP (COMPtotal) and COMP neoepitope (COMPneo) with other cardiovascular markers and clinical parameters could identify symptomatic carotid stenosis. APPROACH AND RESULTS: Blood samples were collected from patients with symptomatic carotid stenosis (stenosis, n=50), patients with stroke without carotid stenosis but small plaques (plaque, n=50), and control subjects (n=50). COMPtotal and COMPneo were measured using an ELISA. Ninety-two cardiovascular disease markers were measured by the Olink CVD kit. The presence of native COMP and COMPneo was determined by immunohistochemistry. The concentration of COMPneo was higher and COMPtotal was lower in the stenosis group. When the concentration was compared between the stenosis and control groups, IL-1ra (interleukin-1 receptor antagonist protein), IL6 (interleukin-6), REN (Renin), MMP1 (matrix metalloproteinase-1), TRAIL-R2 (tumor necrosis factor-related apoptosis-inducing ligand receptor 2), ITGB1BP2 (integrin beta 1 binding protein 2), and COMPneo were predictive of stenosis. Conversely, KLK6 (kallikrein-6), COMPtotal, NEMO (nuclear factor-kappa-B essential modulator), SRC (Proto-oncogene tyrosine-protein kinase Src), SIRT2 (SIR2-like protein), CD40 (cluster of differentiation 40), TF (tissue factor), MP (myoglobin), and RAGE (receptor for advanced glycation end-products) were predictive of the control group. Model reproducibility was good with the receiver operating characteristic plot area under the curve being 0.86. When comparing the plaque group and stenosis group, COMPneo, GAL (galanin), and PTX3 (pentraxin-related protein PTX3) were predictive of stenosis. Model reproducibility was excellent (receiver operating characteristic plot area under the curve 0.92). COMPneo was detected in smooth muscle-, endothelial-, and foam-cells in carotid stenosis. CONCLUSIONS: Degradation of COMP may be associated with atherosclerosis progression and generation of a specific COMP fragment—COMPneo. This may represent a novel biomarker that together with COMPtotal and other risk-markers could be used to identify symptomatic carotid stenosis. Lippincott Williams & Wilkins 2021-01-21 2021-03 /pmc/articles/PMC7901532/ /pubmed/33472398 http://dx.doi.org/10.1161/ATVBAHA.120.314720 Text en © 2021 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Clinical and Population Studies
Sandstedt, Joakim
Vargmar, Karin
Björkman, Kristina
Ruetschi, Ulla
Bergström, Göran
Hultén, Lillemor Mattsson
Skiöldebrand, Eva
COMP (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic Carotid Stenosis
title COMP (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic Carotid Stenosis
title_full COMP (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic Carotid Stenosis
title_fullStr COMP (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic Carotid Stenosis
title_full_unstemmed COMP (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic Carotid Stenosis
title_short COMP (Cartilage Oligomeric Matrix Protein) Neoepitope: A Novel Biomarker to Identify Symptomatic Carotid Stenosis
title_sort comp (cartilage oligomeric matrix protein) neoepitope: a novel biomarker to identify symptomatic carotid stenosis
topic Clinical and Population Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901532/
https://www.ncbi.nlm.nih.gov/pubmed/33472398
http://dx.doi.org/10.1161/ATVBAHA.120.314720
work_keys_str_mv AT sandstedtjoakim compcartilageoligomericmatrixproteinneoepitopeanovelbiomarkertoidentifysymptomaticcarotidstenosis
AT vargmarkarin compcartilageoligomericmatrixproteinneoepitopeanovelbiomarkertoidentifysymptomaticcarotidstenosis
AT bjorkmankristina compcartilageoligomericmatrixproteinneoepitopeanovelbiomarkertoidentifysymptomaticcarotidstenosis
AT ruetschiulla compcartilageoligomericmatrixproteinneoepitopeanovelbiomarkertoidentifysymptomaticcarotidstenosis
AT bergstromgoran compcartilageoligomericmatrixproteinneoepitopeanovelbiomarkertoidentifysymptomaticcarotidstenosis
AT hultenlillemormattsson compcartilageoligomericmatrixproteinneoepitopeanovelbiomarkertoidentifysymptomaticcarotidstenosis
AT skioldebrandeva compcartilageoligomericmatrixproteinneoepitopeanovelbiomarkertoidentifysymptomaticcarotidstenosis